What are the side effects of opicapone?

The U.S. Food and Drug Administration(FDA) approved opicapone (opicapone) for use with levodopa to reduce the total "off" time each day when Parkinson's disease symptoms return. Opicapone is a catechol-O-methyltransferase (COMT) inhibitor that prevents the breakdown of levodopa so that more levodopa reaches the brain and is converted into dopamine.

Opicapone 50 mg was generally well tolerated in clinical trials, with most events reported as mild or moderately severe. The most common adverse reactions (incidence of at least 4%) were dyskinesia, constipation, elevated blood creatine kinase, hypotension/syncope, and weight loss. A total of 8% of patients receiving 50 mg and 6% of patients receiving placebo discontinued treatment due to adverse events. The most common adverse reaction leading to discontinuation was dyskinesia. Attention should also be paid to the occurrence of cardiovascular effects of the combination, somnolence and somnolence, hypotension/syncope, dyskinesia, hallucinations and psychosis, impulse control/obsessive-compulsive disorder, hyperthermia and confusion after discontinuation of the drug. There is currently no specific antidote for overdose of opicapone, and as a general measure, removal of the foreign body by gastric lavage and/or inactivation of the foreign body by the use of activated charcoal should be considered.

Opicapone has not yet been launched in the country, so it is not covered by medical insurance. The European version of Opicapone’s original drug specifications listed overseasThe price per box of 50mg*90 capsules is around RMB 6,000 (the price may fluctuate due to the exchange rate). There is currently no generic version of Opicapone on the market. For more drug information and specific prices, please consult Yaode’s medical consultant.